门控SPECT心肌灌注显像评估心室不同步对CRT心力衰竭患者管理的价值:VISION-CRT研究
VISION-CRT是一项多中心前瞻性研究,纳入195例接受心脏再同步化治疗(CRT)的心力衰竭患者,术前及术后6个月行门控SPECT心肌灌注显像(gSPECT MPI)。结果显示,左心室相位标准差(PSD)的变化与主要临床结局相关(OR 1.04,95%CI 1.01-1.07,P=.007),而CRT导线是否置于最晚机械激动存活节段(vSOLA)与结局无显著关联(OR 1.53,95%CI 0.71-3.28)。
要点
- gSPECT MPI测得的左心室不同步改善可预测CRT后6个月临床结局。
- 基线不同步程度与主要结局无关。
- 导线是否置于vSOLA与主要结局无显著关联。
核心结论
- gSPECT MPI评估的左心室不同步改善可预测CRT患者的临床结局,而导线置于靶目标节段未显示显著预测价值。
研究设计与样本
- 多中心前瞻性研究,来自8个国家10个中心,连续纳入195例接受CRT的患者。
- 所有患者均在CRT术前和术后6个月接受gSPECT MPI,操作者不知晓gSPECT MPI结果。
- 采用17节段模型自动测定区域左心室不同步(相位标准差)和最晚机械激动的存活节段(vSOLA)。
主要发现
- 6个月时左心室相位标准差(PSD)平均变化为10.5°。
- 基线不同步与主要结局无关,但LV PSD自基线的变化与主要结局相关(OR 1.04,95%CI 1.01-1.07,P=.007)。
- LV PSD变化对主要结局的AUC为0.78(95%CI 0.66-0.90)。
- LV PSD改善4°时对良好结局的阳性似然比最高,为7.4。
关键数值与推荐
- 主要结局定义为以下至少一项改善:NYHA心功能分级改善≥1级、LVEF提高≥5%、收缩末期容积减少≥15%、MLHFQ评分改善≥5分。
- 23%的患者CRT导线置于vSOLA,42%置于vSOLA或距其10°以内的节段。
- 导线置于靶目标与主要结局无显著关联(OR 1.53,95%CI 0.71-3.28)。
临床怎么用
- 可利用gSPECT MPI评估左心室不同步及其改善来预测CRT患者的临床结局。
- 导线是否置于vSOLA未显示与结局显著相关,提示需综合评估其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Placing the left ventricular (LV) lead in a viable segment with the latest mechanical activation (vSOLA) may be associated with optimal cardiac resynchronization therapy (CRT) response. We assessed the role of gated SPECT myocardial perfusion imaging (gSPECT MPI) in predicting clinical outcomes at 6 months in patients submitted to CRT. METHODS: Ten centers from 8 countries enrolled 195 consecutive patients. All underwent gSPECT MPI before and 6 months after CRT. The procedure was performed as per current guidelines, the operators being unaware of gSPECT MPI results. Regional LV dyssynchrony (Phase SD) and vSOLA were automatically determined using a 17 segment model. The lead was considered on-target if placed in vSOLA. The primary outcome was improvement in ≥1 of the following: ≥1 NYHA class, left ventricular ejection fraction (LVEF) by ≥5%, reduction in end-systolic volume by ≥15%, and ≥5 points in Minnesota Living With Heart Failure Questionnaire (MLHFQ). RESULTS: Sixteen patients died before the follow-up gSPECT MPI. The primary outcome occurred in 152 out of 179 (84.9%) cases. Mean change in LV phase standard deviation (PSD) at 6 months was 10.5°. Baseline dyssynchrony was not associated with the primary outcome. However, change in LV PSD from baseline was associated with the primary outcome (OR 1.04, 95% CI 1.01-1.07, P = .007). Change in LV PSD had an AUC of 0.78 (0.66-0.90) for the primary outcome. Improvement in LV PSD of 4° resulted in the highest positive likelihood ratio of 7.4 for a favorable outcome. In 23% of the patients, the CRT lead was placed in the vSOLA, and in 42% in either this segment or in a segment within 10° of it. On-target lead placement was not significantly associated with the primary outcome (OR 1.53, 95% CI 0.71-3.28). CONCLUSION: LV dyssynchrony improvement by gSPECT MPI, but not on-target lead placement, predicts clinical outcomes in patients undergoing CRT.
引用
- Peix A, Karthikeyan G, Massardo T, et al. Value of intraventricular dyssynchrony assessment by gated-SPECT myocardial perfusion imaging in the management of heart failure patients undergoing cardiac resynchronization therapy (VISION-CRT). J Nucl Cardiol. 2019. PMID: 30684258. doi:10.1007/s12350-018-01589-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。